High Content Screening Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

High Content Screening Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The high Content Screening Market is poised to grow at a CAGR of 8.74% over the forecast period (2022-2027).

The outbreak of COVID-19 has turned the spotlight on the toxicology drug screening market as most of the biopharmaceutical players are involved in the development of novel therapeutics against the SARS-CoV2 virus. Due to the increase in drug discovery, there was an increasing demand for drug testing products and services to monitor and evaluate the toxicity of a certain vaccine before commercializing it to the market. Due to this, the pandemic had a positive impact on the market studied. According to the research article published in the American Chemical Society Pharmacology and Translational Science, 2020, new potential therapeutics for COVID-19 identified with a combined virtual and experimental screening strategy and selected from among the already approved drugs were studied to screen for structural similarity against a library of almost 4000 approved drugs with hydroxychloroquine (HCQ) as a reference drug. The study proposed zuclopenthixol, nebivolol, and amodiaquine as potential candidates for clinical trials against the early phase of the SARS-CoV-2 infection and remdesivir and favipiravir therapeutics as potential adjuvants in COVID-19 treatment. With rising use of high content screening for such studies. the COVID-19 made a signifcant impact on the market studied.

The need for cost containment in pharmaceutical research and development, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market.Under the conventional method of toxicity studies, large libraries are screened in search of potential drug candidates. The traditional method is expensive, resource- and time-consuming, and has a low success rate. Consequently, high content screening (HCS) solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in-vitro toxicity testing by reducing the time and cost. The increasing number of contract research organizations providing HCS outsourcing services and the application of HCS in personalized medicine present significant growth opportunities in the market.

The recent technological developments by the market players and researchers, rising investments, and rising research and development activities worldwide are contributing to the growth of the market studied. In April 2022, CytoTronics received USD 9.25 million in initial seed funding, led by Anzu Partners with participation from Milad Alucozai (BoxOne Ventures) and institutional investors. This funding will allow the company to commercialize its research-demonstrated devices for cell-based drug screening in multiple areas such as oncology, gastroenterology, cardiology, and neurology. Such investments will allow companies to expand their offerings in terms of bringing technologically advanced products to the market for drug screening purposes.

Hence, with the above-mentioned factors, it is believed that the market studied will witness a healthy growth over the forecast period.

Key Market TrendsFlow Cytometry is Expected to Witness Healthy Growth Over the Forecast Period

Flow cytometry is one of the established technologies used in many research and clinical laboratories. ​Previously, flow cytometry was significantly restricted because of its limitations in handling scores of samples. However, with unparalleled advances in cell-based analysis and screening in recent years, this technique has been utilized as a powerful screening tool. ​

Its primary users are immunologists and hematologists who use it for cell sorting and analysis. Increasing requirements for processing a larger number of patient samples have led to the development of automated tube loading carousels and, later, multi-well plate-based sampling systems. The advantages of flow cytometry, like the high-speed quantitative and high-content analysis of cells, make the technique an attractive technology for drug discovery applications. ​In June 2020, a research work published in the Journal of Pharmacology and Experimental Therapeutics studied the use of a fluorescence cytometry plate reader for cell-based fluorescence imaging assays without washing out reagents to reduce background signals.​ Such applications of flow cytometry in screening are contributing to the growth of the market stidoed.

Flow cytometry is becoming an ideal tool, particularly in an environment where primary cell-based assays are increasingly being deployed to monitor drug responses.​ The increasing use of phenotypic cell-based assays in drug discovery is a major factor driving the flow cytometry market growing. ​The increasing number of drug discovery processes and the need to monitor drug responses are major factors for the growth of flow cytometry. Therefore, the usage is expected to increase in the coming years.​ Additionally, the utilization of flow cytometry in detection of cancer is augmenting the growth of the segment studied.

United States is Expected to Dominate the Market

The United States is expected to have a significant market share over the forecast period in the high content screening market due to the growing research and development activities by pharmaceutical companies, the growing prevalence of chronic diseases in the country, and increasing technological advancements in high content screening methods. Along with it, the launch of new products, rising investments, and adoption of key strategies are expected to boost the market studied.

According to the American Cancer Society’s 2021 report, about 1,898,160 cancer cases (970,250 in males and 927,910 in females) were predicted in 2021 in the United States. The prevalence rate of heart failure in the United States is 6 million, which is 1.8% of its total population, as reported by the American Heart Association in 2021. The increasing number of cardiovascular diseases among patients further increases the need and demand for effective therapeutics for various inherited cardiovascular conditions. This is expected to be one of the major driving factors for the growth of the market studied in the United States.

According to an article published by National Center for Science and Engineering Statistics 2020, the 42 federally funded research and development centers (FFRDCs) in the United States spent USD 23.5 billion on research and development in FY 2020, an annual increase of 3.4%. This increase in expenditure is largely driven by the focus on having a competitive edge over their competitors and high returns on the newly developed product. Therefore, owing to the above-mentioned factors, the market studied is expected to witness strong growth in the United States.

Competitive Landscape

The market for high content screening (HCS) is moderately competitive. For compound profiling applications, many pharmaceutical companies are partnering with contract research organizations to identify potential candidates for drug discovery. The HCS market is highly competitive in nature. Some of the key companies in the market are Agilent Technologies, Cytiva, Becton Dickinson and Company, Bio-rad Laboratories, and Thermofisher Scientific, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.